08:36:44 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMERK Equities
Nykode Therapeutics är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.


2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-16 Kvartalsrapport 2022-Q1
2022-05-13 Ordinarie utdelning NYKD 0.00 NOK
2022-05-12 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning NYKD 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split NYKD 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma
2021-05-05 14:28:09
Oslo, Norway, May 05, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, today announced the appointment of Dr. Volck, M.D., Ph.D. to
its Board of Directors.

"I am excited to welcome Dr. Birgitte Volck to our Board. Dr. Volck is a
seasoned R&D executive with broad international experience. Her valuable
expertise will help guide and support Vaccibody in this transformational period
of expansion and clinical pipeline acceleration." said Anders Tuv, Chairperson
of Vaccibody AS.

Dr. Volck has over 20 years of leadership experience in the biotechnology and
pharmaceutical industry.

Dr. Volck has served as the President R&D at AVROBIO Inc. (Nasdaq), a clinical
stage gene therapy company. Prior to this, she served as head of Research and
Development, Rare Diseases, for GlaxoSmithKline. Before that, Dr. Volck was the
Chief Medical Officer and Senior Vice President of Development at Swedish Orphan
Biovitrum AB. She has held various positions at Amgen Inc., including Executive
Development Director, Bone, Neuroscience & Inflammation and served as Nordic
Medical Director and Project Director at Genzyme A/S. She currently serves as
Director of Ascendis Pharma A/S (Nasdaq) and Soleno Therapeutics Inc. (Nasdaq).
Dr. Volck received her M.D. and Ph.D. degrees from Copenhagen University,

About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung-, head and neck, renal-, and bladder cancer